PSMA PET Scan

PROCEDURE18 trials

Sponsors

University of Washington, Mayo Clinic, NRG Oncology, Medical University of Vienna, Thomas Jefferson University

Conditions

Adenoid Cystic CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate CarcinomaCastration-Sensitive Prostate CarcinomaMetastatic Breast CarcinomaMetastatic Castration-Resistant Prostate AdenocarcinomaMetastatic Castration-Resistant Prostate CarcinomaMetastatic Lung Non-Small Cell Carcinoma

Phase 1

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

TerminatedNCT05733351

Emory UniversityCastration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2023-08-03End: 2025-06-12Updated: 2025-09-15

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Not yet recruitingNCT06982222

National Cancer Institute (NCI)Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma +4

Start: 2026-03-31End: 2027-02-12Target: 24Updated: 2026-04-03

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT07219147

City of Hope Medical CenterMetastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2026-03-05End: 2028-07-26Target: 30Updated: 2026-01-28

Phase 2

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

RecruitingNCT04175431

University of WashingtonProstate Adenocarcinoma

Start: 2020-09-30End: 2033-07-01Target: 100Updated: 2025-12-18

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Active, not recruitingNCT04895735

Mayo ClinicAdenoid Cystic Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma +1

Start: 2021-07-23End: 2028-02-28Updated: 2026-02-02

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

RecruitingNCT05053152

NRG OncologyOligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma +2

Start: 2022-04-20End: 2029-02-01Target: 194Updated: 2026-01-14

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

TerminatedNCT05676463

Thomas Jefferson UniversityProstate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8

Start: 2022-11-16End: 2025-10-24Updated: 2026-03-03

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

RecruitingNCT05806515

SWOG Cancer Research NetworkProstate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8

Start: 2024-03-01End: 2031-06-01Target: 44Updated: 2026-01-29

PSMA PET Scan and mpMRI for Prostate Cancer Detection

Not yet recruitingNCT05820724

VA Greater Los Angeles Healthcare SystemProstate Cancer Diagnosis

Start: 2023-05-01End: 2026-05-01Target: 100Updated: 2023-04-24

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Active, not recruitingNCT05960578

University of WashingtonMetastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8

Start: 2024-05-23End: 2026-04-07Updated: 2026-03-12

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

Not yet recruitingNCT06129851

University of Kansas Medical CenterStage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8

Start: 2023-11-20End: 2026-10-23Target: 90Updated: 2023-11-13

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

RecruitingNCT06216249

Jonsson Comprehensive Cancer CenterProstate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

Start: 2024-08-01End: 2028-12-31Target: 90Updated: 2026-03-10

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

RecruitingNCT06632977

Alliance for Clinical Trials in OncologyCastration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2025-02-06End: 2034-10-11Target: 474Updated: 2026-03-04

Phase 3

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

RecruitingNCT06931340

Alliance for Clinical Trials in OncologyCastration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2025-12-01End: 2039-05-08Target: 1260Updated: 2026-03-04

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Not yet recruitingNCT07200830

Alliance for Clinical Trials in OncologyMetastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2025-10-08End: 2034-09-09Target: 1524Updated: 2025-10-01

Unknown Phase

Comparison of PET Imaging Patterns With PSMA and AR Expression in Prostate Cancer and Bladder Cancer

CompletedNCT05109884

Medical University of ViennaProstate Cancer

Start: 2020-02-01End: 2021-04-19Updated: 2023-03-17

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

RecruitingNCT05438563

Mayo ClinicProstate Carcinoma, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8

Start: 2022-04-06End: 2027-03-07Target: 100Updated: 2025-09-09

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Not yet recruitingNCT07468903

Jonsson Comprehensive Cancer CenterProstate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8

Start: 2026-04-04End: 2032-04-04Target: 45Updated: 2026-03-19

Related Papers

Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer.

2026-03-05

A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from non-adenoid cystic cohort.

Journal of Clinical Oncology2025-05-28

A randomized phase 2 trial of flexible and extended dosing of <sup>177</sup> Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT): Trial in progress update.

Journal of Clinical Oncology2025-05-28

Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker based study (Alliance A032102).

Journal of Clinical Oncology2025-05-28

A randomized phase 2 trial in progress of flexible and extended dosing of <sup>177</sup>Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT).

Journal of Clinical Oncology2024-06-011 citations

TRAMP study: A phase 2 trial of tumor necrosis factor-α blockade and AR inhibition in men with CRPC.

Journal of Clinical Oncology2024-06-01

SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline <i>BRCA1/2</i> mutations.

Journal of Clinical Oncology2024-01-29

NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).

Journal of Clinical Oncology2023-02-203 citations

A phase II study of pemetrexed and pembrolizumab in recurrent and/or metastatic salivary gland malignancies.

Journal of Clinical Oncology2022-06-011 citations